 Apellis Pharmaceuticals Inc NASDAQ: APLS announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy GA lesion growth. These data will be included in the U.S. marketing application that the. 